Latest Press

Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration

06 sep 2022

Read more
Latest Publication

Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase

22 feb 2021

Read more
Latest Event

BIO-Europe 2022

24 okt 2022

Read more

"Beactica has a rich and unique history of creating impact and has always been dedicated to excellence and innovation. We use our passion for science combined with the exceptional skills, expertise and scientific knowledge of our team to discover and develop novel cancer therapeutics and make a difference where it really matters."

- Per Källblad Ph.D. Chief Executive Officer

Learn More

A growing pipeline of novel therapeutics

Inspired by the possibility of improving the prospects for patients living with life-threatening conditions, we are setting the pace for years to come in the continuously evolving cancer drug development landscape. Our growing team of future-thinking scientists and development professionals are driving the advancement of multiple life-saving therapeutics into the clinic to get them to the patients that need them.

Learn More

Maximising clinical gains with synthetic lethality

With a clear vision and focus, we are leveraging synthetic lethality vulnerabilities to meticulously develop breakthrough solutions that specifically and effectively target genetically defined cancers.

Learn More

Offering compelling investment opportunities

With support from purposeful, mutually beneficial investments, we deliver value to patients and stakeholders. Our historic success in lead generation using our partner-validated drug development technology offers a secure foundation for the growth and advancement of our proprietary novel therapeutics to be progressed into the clinic.

Learn More
watch

Beactica Therapeutics presentation at NLSDays 2018

Beactica's CEO, Dr Per Källblad, gives presentation entitled "Targeting LSD1 in aggressive brain tumors" at Nordic Life Science Days (NLSDays) in Stockholm (10-12 Sep 2018)

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates